Lonza Group Stock Shows Every Sign Of Being Significantly Overvalued

Author's Avatar
GF Value
Apr 18, 2021
Article's Main Image

The stock of Lonza Group (OTCPK:LZAGY, 30-year Financials) is believed to be significantly overvalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $61.03 per share and the market cap of $45.3 billion, Lonza Group stock gives every indication of being significantly overvalued. GF Value for Lonza Group is shown in the chart below.

Lonza Group GF Value Chart

Because Lonza Group is significantly overvalued, the long-term return of its stock is likely to be much lower than its future business growth, which is estimated to grow 4.14% annually over the next three to five years.

Link: These companies may deliever higher future returns at reduced risk.

It is always important to check the financial strength of a company before buying its stock. Investing in companies with poor financial strength have a higher risk of permanent loss. Looking at the cash-to-debt ratio and interest coverage is a great way to understand the financial strength of a company. Lonza Group has a cash-to-debt ratio of 0.13, which is in the bottom 10% of the companies in the industry of Medical Diagnostics & Research. The overall financial strength of Lonza Group is 5 out of 10, which indicates that the financial strength of Lonza Group is fair. This is the debt and cash of Lonza Group over the past years:

debt and cash

Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Lonza Group has been profitable 10 over the past 10 years. Over the past twelve months, the company had a revenue of $4.8 billion and earnings of $1.262 a share. Its operating margin is 20.83%, which ranks better than 81% of the companies in the industry of Medical Diagnostics & Research. Overall, the profitability of Lonza Group is ranked 7 out of 10, which indicates fair profitability. This is the revenue and net income of Lonza Group over the past years:

Revnue and Net Income

Growth is probably the most important factor in the valuation of a company. GuruFocus research has found that growth is closely correlated with the long term stock performance of a company. A faster growing company creates more value for shareholders, especially if the growth is profitable. The 3-year average annual revenue growth of Lonza Group is -3.2%, which ranks worse than 70% of the companies in the industry of Medical Diagnostics & Research. The 3-year average EBITDA growth rate is 6.6%, which ranks in the middle range of the companies in the industry of Medical Diagnostics & Research.

Another way to evaluate a company's profitability is to compare its return on invested capital (ROIC) to its weighted cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the ROIC is higher than the WACC, it indicates that the company is creating value for shareholders. Over the past 12 months, Lonza Group's ROIC was 6.47, while its WACC came in at 3.24. The historical ROIC vs WACC comparison of Lonza Group is shown below:

ROIC vs WACC

In closing, The stock of Lonza Group (OTCPK:LZAGY, 30-year Financials) is believed to be significantly overvalued. The company's financial condition is fair and its profitability is fair. Its growth ranks in the middle range of the companies in the industry of Medical Diagnostics & Research. To learn more about Lonza Group stock, you can check out its 30-year Financials here.

To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.

Rating:
0 / 5 (0 votes)
Author's Avatar